KR20180077180A - 트리테르펜 사포닌 유사체 - Google Patents

트리테르펜 사포닌 유사체 Download PDF

Info

Publication number
KR20180077180A
KR20180077180A KR1020187012783A KR20187012783A KR20180077180A KR 20180077180 A KR20180077180 A KR 20180077180A KR 1020187012783 A KR1020187012783 A KR 1020187012783A KR 20187012783 A KR20187012783 A KR 20187012783A KR 20180077180 A KR20180077180 A KR 20180077180A
Authority
KR
South Korea
Prior art keywords
group
nitrogen
independently selected
oxygen
sulfur
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187012783A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 와이 진
에릭 키아
테하다 알베르토 페르난데즈
제프리 가드너
제이슨 루이스
필립 리빙스톤
제이 타일러 마틴
라스 노르드스트럼
네이가 바라 키쇼어 필라세티
고빈드 라구패씨
데릭 탄
Original Assignee
아쥬반스 테크놀로지스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아쥬반스 테크놀로지스 인코포레이티드 filed Critical 아쥬반스 테크놀로지스 인코포레이티드
Publication of KR20180077180A publication Critical patent/KR20180077180A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06—Fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
KR1020187012783A 2015-11-06 2016-11-04 트리테르펜 사포닌 유사체 Ceased KR20180077180A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562252296P 2015-11-06 2015-11-06
US62/252,296 2015-11-06
US201562268837P 2015-12-17 2015-12-17
US62/268,837 2015-12-17
PCT/US2016/060564 WO2017079582A1 (en) 2015-11-06 2016-11-04 Triterpene saponin analogues

Publications (1)

Publication Number Publication Date
KR20180077180A true KR20180077180A (ko) 2018-07-06

Family

ID=58662549

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187012783A Ceased KR20180077180A (ko) 2015-11-06 2016-11-04 트리테르펜 사포닌 유사체

Country Status (12)

Country Link
US (5) US20180327436A1 (cg-RX-API-DMAC7.html)
EP (2) EP4001290A1 (cg-RX-API-DMAC7.html)
JP (3) JP6900385B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180077180A (cg-RX-API-DMAC7.html)
CN (2) CN112812143A (cg-RX-API-DMAC7.html)
AU (1) AU2016349693B2 (cg-RX-API-DMAC7.html)
CA (1) CA3003483C (cg-RX-API-DMAC7.html)
CL (1) CL2018001192A1 (cg-RX-API-DMAC7.html)
IL (3) IL286493B (cg-RX-API-DMAC7.html)
SG (2) SG10202012205XA (cg-RX-API-DMAC7.html)
WO (1) WO2017079582A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201802891B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2950750C (en) * 2014-05-30 2023-01-10 David Y. Gin Minimal saponin analogues, synthesis and use thereof
EP4001290A1 (en) * 2015-11-06 2022-05-25 Adjuvance Technologies, Inc. Triterpene saponin analogues
US20210299237A1 (en) * 2017-04-13 2021-09-30 Adjuvance Technologies, Inc. Triterpene saponin synthesis, intermediates and adjuvant combinations
WO2018200656A1 (en) * 2017-04-25 2018-11-01 Adjuvance Technologies, Inc. Triterpene saponin analogues
US20210283248A1 (en) * 2017-04-25 2021-09-16 Adjuvance Technologies, Inc. Triterpene saponin analogues
CN111212846B (zh) * 2017-10-16 2023-05-26 佐剂技术公司 三萜皂苷类似物
US20230128815A1 (en) * 2020-03-23 2023-04-27 Adjuvance Technologies, Inc. Adjuvant compounds, salt forms, and formulations
CN115867304A (zh) 2020-05-19 2023-03-28 欧萨尔普罗席纳有限公司 用于治疗阿兹海默症的多抗原决定基疫苗
AU2021321549A1 (en) 2020-08-07 2023-03-09 Othair Prothena Limited Multiepitope vaccine for the treatment of alzheimer's disease
WO2023056089A1 (en) 2021-10-03 2023-04-06 Eisai R&D Management Co., Ltd. Immunological adjuvant formulations comprising tlr4 agonist e6020
US20250025550A1 (en) * 2021-11-08 2025-01-23 Adjuvance Technologies, Inc. Adjuvant compounds and formulations
EP4190359A1 (en) 2021-12-03 2023-06-07 Asociación Centro de Investigación Cooperativa en Biociencias - CIC bioGUNE Saponin-based adjuvants and vaccines
WO2023139145A1 (en) 2022-01-19 2023-07-27 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Saponin-based adjuvants and vaccines
CN117106004A (zh) * 2022-05-17 2023-11-24 北京科兴中维生物技术有限公司 三萜皂苷化合物及其制备方法及应用
WO2024218268A1 (en) 2023-04-20 2024-10-24 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Saponin derivatives as adjuvants and photoaffinity probes
WO2024261351A2 (en) 2024-05-08 2024-12-26 Vaccine Formulation Institute Ch Ltd. Immunologically active saponin fractions and adjuvant formulations

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5341202B2 (cg-RX-API-DMAC7.html) 1974-03-12 1978-11-01
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US5231112A (en) 1984-04-12 1993-07-27 The Liposome Company, Inc. Compositions containing tris salt of cholesterol hemisuccinate and antifungal
US4769239A (en) 1984-08-21 1988-09-06 Merck & Co., Inc. Vaccine against varicella-zoster virus
US4684479A (en) 1985-08-14 1987-08-04 Arrigo Joseph S D Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures
US6759057B1 (en) 1986-06-12 2004-07-06 The Liposome Company, Inc. Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
IE60901B1 (en) 1986-08-21 1994-08-24 Vestar Inc Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
US6406713B1 (en) 1987-03-05 2002-06-18 The Liposome Company, Inc. Methods of preparing low-toxicity drug-lipid complexes
US5583112A (en) 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
AU598958B2 (en) 1987-11-12 1990-07-05 Vestar, Inc. Improved amphotericin b liposome preparation
US5215680A (en) 1990-07-10 1993-06-01 Cavitation-Control Technology, Inc. Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles
CA2139515C (en) 1992-07-17 2008-12-23 Gary B. Calandra Method for preventing zoster or alleviating varicella related post-herpetic neuralgia
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP0929293B1 (en) 1996-08-23 2003-10-22 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
WO1998016201A1 (en) 1996-10-11 1998-04-23 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
AU725257B2 (en) 1996-10-15 2000-10-12 Transave, Inc. N-acyl phosphatidylethanolamine-mediated liposomal drug delivery
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
WO1999011241A1 (en) 1997-09-05 1999-03-11 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
US6262029B1 (en) * 1998-08-14 2001-07-17 Galenica Pharmaceuticals, Inc. Chemically modified saponins and the use thereof as adjuvants
WO2001015727A2 (en) 1999-09-02 2001-03-08 Antigenics Inc. Compositions of immunostimulatory polymers and saponin adjuvants and uses thereof
GB0401239D0 (en) 2004-01-21 2004-02-25 Molecularnature Ltd Adjuvant compositions
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0700562D0 (en) * 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
DK2148697T3 (da) 2007-05-24 2012-12-17 Glaxosmithkline Biolog Sa Lyofiliseret CPG indeholdende WT-1-sammensætning
EP2234637A2 (en) 2007-12-21 2010-10-06 GlaxoSmithKline Biologicals S.A. Vaccines for malaria
KR102085687B1 (ko) * 2008-04-08 2020-03-06 슬로안-케테링인스티튜트퍼캔서리서치 트리테르펜 사포닌, 그의 합성 방법, 및 그의 용도
CA2720961A1 (en) 2008-04-16 2009-10-22 William Ripley Ballou, Jr. Streptococcus pneumonia vaccine
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
EA026401B1 (ru) 2009-09-02 2017-04-28 Новартис Аг Иммуногенные композиции, содержащие модуляторы активности tlr
EA201391456A1 (ru) 2011-05-17 2014-05-30 Глаксосмитклайн Байолоджикалс С.А. ВАКЦИНА ПРОТИВ Streptococcus pneumoniae
KR102374576B1 (ko) 2011-05-17 2022-03-15 솔리제닉스, 인크. 열안정성 백신 조성물 및 그의 제조방법
US20130309273A1 (en) 2012-05-17 2013-11-21 Kimberly Hassett Thermostable Vaccine Compositions and Methods of Preparing Same
WO2014124860A1 (en) 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Specific pde4b-inhibitors for the treatment of diabetes mellitus
US20150037374A1 (en) 2013-07-31 2015-02-05 Csl Limited Anti-tumor compositions and uses thereof
CA2950750C (en) 2014-05-30 2023-01-10 David Y. Gin Minimal saponin analogues, synthesis and use thereof
WO2016096968A1 (en) 2014-12-18 2016-06-23 Glaxosmithkline Biologicals S.A. Vaccination
EP4001290A1 (en) 2015-11-06 2022-05-25 Adjuvance Technologies, Inc. Triterpene saponin analogues
ES2944947T3 (es) 2015-12-17 2023-06-27 Memorial Sloan Kettering Cancer Center Variantes de triterpeno-saponina, métodos de síntesis y uso de las mismas
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
US20210299237A1 (en) 2017-04-13 2021-09-30 Adjuvance Technologies, Inc. Triterpene saponin synthesis, intermediates and adjuvant combinations
US20210283248A1 (en) 2017-04-25 2021-09-16 Adjuvance Technologies, Inc. Triterpene saponin analogues
WO2018200656A1 (en) 2017-04-25 2018-11-01 Adjuvance Technologies, Inc. Triterpene saponin analogues
US20200276299A1 (en) 2017-09-08 2020-09-03 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
CN111212846B (zh) 2017-10-16 2023-05-26 佐剂技术公司 三萜皂苷类似物
US20190275134A1 (en) 2018-03-12 2019-09-12 Janssen Pharmaceuticals, Inc Vaccines against urinary tract infections
JP2023500676A (ja) 2019-11-05 2023-01-10 アジュバンス・テクノロジーズ・インコーポレーテッド 水痘帯状疱疹

Also Published As

Publication number Publication date
AU2016349693B2 (en) 2022-08-11
US20240327443A1 (en) 2024-10-03
US20180327436A1 (en) 2018-11-15
SG11201803594TA (en) 2018-05-30
JP2021152043A (ja) 2021-09-30
SG10202012205XA (en) 2021-01-28
AU2016349693A1 (en) 2018-05-17
US10906926B2 (en) 2021-02-02
CN108778289A (zh) 2018-11-09
US20210002316A1 (en) 2021-01-07
ZA201802891B (en) 2020-01-29
WO2017079582A1 (en) 2017-05-11
IL259145B (en) 2021-09-30
IL286493B (en) 2022-07-01
IL293848A (en) 2022-08-01
CA3003483C (en) 2022-09-13
CN108778289B (zh) 2020-11-17
CL2018001192A1 (es) 2018-11-23
JP2018537527A (ja) 2018-12-20
JP6900385B2 (ja) 2021-07-07
IL293848B2 (en) 2025-02-01
EP3370730A1 (en) 2018-09-12
IL259145A (en) 2018-06-28
IL293848B1 (en) 2024-10-01
US20230219991A1 (en) 2023-07-13
JP2023012519A (ja) 2023-01-25
US20200239509A1 (en) 2020-07-30
IL286493A (en) 2021-10-31
CN112812143A (zh) 2021-05-18
CA3003483A1 (en) 2017-05-11
US12037355B2 (en) 2024-07-16
EP4001290A1 (en) 2022-05-25
EP3370730A4 (en) 2019-07-31

Similar Documents

Publication Publication Date Title
KR20180077180A (ko) 트리테르펜 사포닌 유사체
JP5706815B2 (ja) トリテルペンであるサポニン、その合成法および使用
KR102706661B1 (ko) 트리테르펜 사포닌 유사체
JP7177082B2 (ja) トリテルペンサポニン類似物
JP2021152043A5 (cg-RX-API-DMAC7.html)
JP2022169763A (ja) トリテルペンサポニン合成、中間体及びアジュバントの組み合わせ
HK40042493A (en) Triterpene saponin analogues
HK40016652A (zh) 三萜皂苷类似物
HK40016648A (en) Triterpene saponin analogues
HK1260769B (en) Triterpene saponin analogues
HK1260769A1 (en) Triterpene saponin analogues

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180503

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PN2301 Change of applicant

Patent event date: 20190419

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210317

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230927

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240403

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230927

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I